Featured news from NHIVNA
HIV-related news from NAM
Medicines Patent Pool looks at hepatitis C
Keith Alcorn, 2015-09-08 16:40:00
Greg Perry, Executive Director of the Medicines Patent Pool,
told delegates at the World Hepatitis Summit in Glasgow last week that the
organisation was considering how it could act to speed up and expand access to
direct-acting antivirals for lower- and middle-income countries, where around
85% of people with hepatitis C are estimated to live.
The Medicines Patent Pool was established with the support
of UNITAID, the international drug and diagnostics purchase fund for HIV,
tuberculosis and malaria, to negotiate voluntary licensing agreements with
pharmaceutical companies that would allow widespread access to low-cost
antiretroviral drugs for HIV treatment. The Medicines Patent Pool was also
designed as a mechanism to overcome barriers to the development of fixed-dose
drug combinations of products from more than one manufacturer, for efficient
delivery of treatment in lower- and middle-income countries.
Since its launch in 2010 the Medicines Patent Pool has
negotiated voluntary licensing agreements with all the major pharmaceutical
companies that allow some or all of their antiretroviral products to be copied
by generic manufacturers for sale at greatly reduced prices in lower- and
Some of the most important drugs used in HIV treatment are
now covered by MPP agreements, although the geographical scope of the
agreements varies between products.
Now the Medicines Patent Pool is weighing whether it can
make a similar difference in the field of viral hepatitis, where access to new
antiviral drugs is very limited outside higher-income countries.
The MPP’s first priority is to negotiate voluntary licensing
agreements that would allow the development of pan-genotypic combinations of
direct-acting antivirals. Pan-genotypic drug combinations should be equally
active against all genotypes of hepatitis C. Although many advocates argue that
pan-genotypic combinations are needed in order to simplify treatment by
dispensing with the need for genotype testing, a greater advantage to a
pan-genotypic combination would be efficacy against all the genotypes present
in lower- and middle-income countries, allowing a larger proportion of the
population with hepatitis C infection to benefit from lower-cost treatment.
Whereas genotype 1 predominates in the high-value markets of Europe and North
America, the mixture of genotypes is far more varied in Asia and Africa. Whereas
all direct-acting antiviral combinations are active against genotype 1, some
are much less potent when used to treat genotype 3. Having one regimen that
suits all patients would vastly simplify treatment by removing the need for a
mosaic of national guidelines to cater for local variations in the genotype
mix, and would overcome delays in registration of multiple products needed to
treat different genotypes.
Dr Isabelle Andrieux-Meyer of Médecins sans Frontières urged
the Medicines Patent Pool to prioritise daclatasvir in order to achieve a
pan-genotypic combination with sofosbuvir – and to forestall a Gilead monopoly
in pan-genotypic treatment.
“Our number one priority is to open up negotiations with
Bristol Myers Squibb [on daclatasvir]. We think they have the most interesting
product,” Greg Perry told delegates. Bristol Myers Squibb has not yet published
voluntary licensing proposals for daclatasvir (Daklinza).
Approximately 85% of people with hepatitis C live in
lower-income or middle-income countries, Homi Hazawi of the Center for Disease
Analysis said, but a major challenge facing all efforts to reduce the price of
hepatitis C treatment lies in the fact that a large number of these people live
in countries such as China, Brazil and Russia which may not be covered by voluntary
licensing deals. A review by the Center for Disease Analysis suggests that
23%-29% of people with hepatitis C live in upper middle-income countries, and
43%-49% in lower middle-income countries.
The only existing voluntary licensing arrangements for
hepatitis C cover Gilead’s products Sovaldi
(sofosbuvir) and Harvoni
(sofosbuvir/ledipasvir). Voluntary licensing to 11 Indian generic manafacturers
allows those companies to market versions of the Gilead products in 101 lower-
and lower middle-income countries, and to combine the agents with other
products not owned by Gilead. Strict anti-diversion measures designed to
prevent the drugs being sold in markets not covered by the licence have also
been agreed, but these terms have been strongly criticised by Médecins
sans Frontières for their potential to harm patient confidentiality and
autonomy. Advocates would like to see less onerous terms and greater coverage
of middle-income countries in future licenses.
Greg Perry believes that the MPP can deliver better deals
through experience and persistence, but warned delegates, “We have to be
realistic. I cannot promise to deliver China or Brazil.”
Some advocates, including Initiative for Medicines, Access
and Knowledge (I-MAK), argue that compulsory licensing by governments will be
necessary in order to achieve access for middle-income countries, but a lawyer
with expertise in compulsory licensing told delegates that he was sceptical
regarding its potential to achieve widespread access to low-cost drugs.
“The best we can do is win a couple of cases once in a while
on a couple of products,” said James Love of Knowledge Ecology International,
which has provided legal advice on compulsory licensing of HIV drugs for over a
Brook Baker of Northeastern University, Boston, warned that
due to the lack of donor funding for hepatitis treatment in lower- and lower
middle-income countries, it will be difficult to create the volume of demand
needed for large reductions in the price of generic versions of direct-acting
“If the volume is not there the market is not very
interesting for generic companies,” said Peter Bayer of the World Health
Organization. Unless governments set up programmes to test and treat for
hepatitis C, generics will remain expensive drugs only available through
private pharmacies, he warned.
"item2671530" id="item2671530" class="object451 item2671530 GenericSideBar basic-text">
For more information on hepatitis visit infohep.org.
Infohep is a project we're working on in partnership with the European Liver Patients Association (ELPA).
"item1439251" id="item1439251" class="object451 item1439251 GenericSideBar topics-related">